MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

By GlobeNewswire

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2026, to discuss the financial results and provide a business update.

A live webcast of the conference call will be available in the Events & Presentations section of MannKind’s Investor Relations website. A replay will remain available in the same location for approximately 90 days following the conference call.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.


Contacts:Investor RelationsKate MirandaEmail: ir@mnkd.comMedia RelationsChristie IacangeloEmail: media@mnkd.com

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk